

**УДК 616.61 – 036.12 – 053.2**

## **DETERMINATION OF ENDOGENOUS CARDIOTONIC STEROIDS IN CHILDREN WITH CHRONIC KIDNEY DISEASE**

**Burlaka Ie.A.****O.O. Bogomolets National Medical University, Department of Pediatrics №4  
Kiev, Ukraine, Tolstogo street 10, 01004**

### **ПОКАЗНИКИ ЕНДОГЕННИХ КАРДІОТОНІЧНИХ СТЕРОЇДНИХ ГОРМОНІВ У ДІТЕЙ З ХРОНІЧНОЮ ХВОРОБОЮ НИРОК**

**Бурлака Є.А.****Національний медичний університет імені О.О. Богомольця, Київ, Україна**

Відомо, що ендogenous кардіотонічні стероїдні гормони можуть відігравати важливу роль в розвитку термінальної стадії хронічної хвороби нирок (ХХН) та її ускладнень у дорослих. Їх роль в розвитку ХХН у дітей є недостатньо вивченою. Мета даного дослідження полягала у визначенні рівнів ендogenous кардіотонічних стероїдних гормонів у дітей хворих на ХХН. Обстежено 22 дитини з ХХН, у яких виявлені підвищені рівні ендogenous маринобуфагеніна (МБГ) у порівнянні з дітьми з групи контролю (n=17). При цьому рівні ендogenous оубаїна (ОБ) не відрізнялись від показника групи контролю. Таким чином, ми припускаємо, що при ХХН підвищений рівень МБГ може викликати інгібування Na/K-ATPase і може бути потенційною мішенню для терапії.

**Ключові слова:** хронічна хвороба нирок, гемодіаліз, маринобуфагенін, оубаїн, Na/K-ATPаза.

### **DETERMINATION OF ENDOGENOUS CARDIOTONIC STEROIDS IN CHILDREN WITH CHRONIC KIDNEY DISEASE**

**Burlaka Ie.A.****O.O. Bogomolets National Medical University**

Previous reports demonstrated that digitalis-like cardiotonic steroids (CTS) may contribute to the pathogenesis of end-stage renal disease and its complications. The role of CTS in nature of CKD in pediatric patients is not fully studied. The goal of the present study was to define the levels of CTS in pediatric patients with chronic kidney disease (CKD). In 22 patients with CKD plasma marinobufagenin (MBG) but not endogenous ouabain (EO) was increased as compared to that in 17 healthy individuals. Thus, we speculate that in chronic renal failure elevated levels of bufadienolide CTS MBG may cause the Na/K-ATPase inhibition and may represent a potential target for therapy.


**Keywords:** chronic kidney disease, hemodialysis, marinobufagenin, ouabain, Na/K-ATPase.**Address for correspondence:****Burlaka Ie.A.** – MD, PhD. O.O. Bogomolets National Medical University, Department of Pediatrics №4, Kiev, Ukraine, Tolstogo street 10, 01004. E-mail address – evgbur1982@gmail.com

## Introduction

Endogenous cardiotoxic steroids (CTS), also called digitalis-like factors, have been postulated to play important roles in health and disease for nearly half a century [1].

For more than 200 years, digitalis, a cardiotoxic steroid, has been used to treat congestive heart failure. The endogenous cardiotoxic steroids ouabain and marinobufagenin have been identified in humans. Cardiotoxic steroids are considered to be important in the regulation of renal sodium transport and arterial pressure, control of cell growth, apoptosis and fibrosis, among other processes [2].

Almost all of the newly detected mammalian steroid hormones were previously isolated as cardiotoxic constituents and toxins from plants and amphibians. Cardiotoxic steroids or cardiac glycosides are specific ligands of the sodium pump ( $\text{Na}^+/\text{K}^+-\text{ATPase}$ ). Endogenous cardiotoxic steroids (Figure 1) have been extracted from mammalian tissues such as hypothalamus [3], heart [4] and adrenal gland [5]. Ouabain (g-Strophanthin) was identified in human blood plasma [6].



**Figure 1. Cardiotoxic steroids identified in mammalian tissues.**

CTSs act as physiological regulators of sodium pump activity and are implicated in regulation of natriuresis and vascular tone [7]. It has been shown that they are increased in end-stage renal disease in adults [8]. However, this remains to be unclear in pediatric patients.

In this study we determined the level of CTS in children with different stages of kidney function reduction due to glomerular and tubular diseases. Values of CTS were related to serum creatinine levels.

## Method

Twenty-two patients with CKD of different stages were included in this study. Of the patients, 5 were on hemodialysis (HD). The cause of CKD was chronic glomerulonephritis (11 patients), pyelonephritis (2 patients), congenital renal dysplasia (9 patients). None of the subjects studied had ever been administered digitalis

drugs. All patients were divided into 4 experimental groups regarding the glomerular filtration rate (GFR) based on serum creatinine levels (Table 1) [9].

**Table 1. Stages of chronic kidney disease.**

Stage	Description	eGFR (mL/min)
1	Kidney damage with normal or $\uparrow$ GFR	$\geq 90$
2	Kidney damage with mild $\downarrow$ GFR	60–89
3	Moderate $\downarrow$ GFR	30–59
4	Severe $\downarrow$ GFR	15–29
5	Kidney failure	<15 or dialysis

For measurement of CTS, plasma samples were extracted using C18 SepPak cartridges (Waters Inc., Cambridge, MA). This assay is based on competition between immobilized antigen (MBG-glycoside-thyroglobulin) and MBG. The EO assays were based on a similar principle.

The results are presented as box-plots. To determine whether the differences among the groups were significant, two-way ANOVA followed by Fisher-LSD post-hoc test was used. If the distribution of the variables was not parametric, the data were analyzed using the non-parametric Mann-Whitney test. The comparisons between groups were made using Kruskal-Wallis one-way ANOVA on ranks with pair-wise multiple comparisons made by Dunn's method. The statistical significance level was defined as  $P < 0.05$ .

## Results

All patients from experimental and control group were analyzed for age, sex, body weight. Patients with CKD did not differ significantly from the control group with respect to all mentioned above parameters.

We measured levels of both CTS in plasma of CKD patients and controls. As presented in Figure 2, patients with CKD had 3.5-fold greater plasma levels of MBG as compared to that in the control group. Moreover, the gradual increase of plasma MBG levels were found between the progressive stages of CKD. Whereas the EO concentrations of this hormone in patients with CKD were not different from control values.





Figure 2. CTS levels in patients with CKD and controls.

We analyzed CTS levels in CKD patients with arterial hypertension. The results show that both CTS documented at higher levels in hypertensive patients. Patients with arterial hypertension identified in CKD 3 group and hemodialysis patients (Figure 3).





Figure 3. CTS levels in children with CKD in relation arterial hypertension presence.

Discussion

The major findings of the present study are that levels of CTS in patients with chronic renal failure exhibit a pattern where MBG rather than EO becomes elevated in pediatric patients with CKD. Since in chronic renal failure CTS represent potentially important therapeutic targets, the importance of this finding in pathogenesis of CKD is obvious.

Previously, three endogenous CTS (ouabain, marinobufagenin, digoxin) were shown to balance blood pressure in experimental animals [10]. Here we found the direct relation of CTS levels in CKD patients and arterial hypertension. Previously shown that the circulating levels of EO, MBG and telocinobufagin are increased dramatically in rat with partial nephrectomy. There is renal fibrosis associated with elevated MBG whereas the sustained elevation of circulating EO or ouabain causes podocyte damage and proteinuria and these effects can be blocked by the ouabain receptor antagonist, rostafuroxin which blocks ouabain binding to the Na<sup>+</sup> pump without causing inhibition of ion transport [11]. We found no differences in circulating EO in CKD patients. This might be explained by un-known compensative mechanisms preserving progression of ouabain-induced damages in CKD patients with late CKD stages and uremia. In contrast, MBG levels gradually increased in patients with progressive CKD. The highest levels documented in HD patients meaning. This may have an evidence that endogenous MBG is dealing with renal fibrosis and increased blood pressure in this cohort of patients.

Overall understanding the functions of CTS in CKD is still quite incomplete. However, the importance of this class of hormones seems to be considerable. Taking to the account that endogenous CTS exhibit physiological functions that go far beyond regulation of sodium transport, natriuresis, and blood pressure and include regulation of cell growth and differentiation, apoptosis and proliferation [12] makes this area dramatically important from the clinical point of view. Dysregulation of these hormones seems to play an important role in a number of diseases including progressive CKD. We propose that expanding our understanding of this class of hormones will lead to novel and effective therapeutic strategies of great relevance to optimizing CKD.

## References

1. Riganti C. et al. Pleiotropic effects of cardioactive glycosides. *Curr. Med. Chem.* – 2011. – 18: 872.
2. Lingrel J.B. The physiological significance of the cardiotonic steroid/ouabain-binding site of the Na,K-ATPase. *Annu Rev Physiol.* – 2010. - 72: 395–412.
3. Mathews W.R., DuCharme D.W., Hamlyn J.M. et al. Mass spectral characterization of an endogenous digitalis-like factor from human plasma. *Hypertension.* – 1991. - 17: 930–935.
4. Komiyama Y., Nishimura N., Munakata M. et al. Identification of endogenous ouabain in culture supernatant of PC12 cells. *J. Hypertens.* – 2001. - 19: 229–236.
5. Doris P.A., Hayward-Lester A., Bourne D., Stocco D.M. Ouabain production by cultured adrenal cells. *Endocrinology.* – 1996. – 137: 533–539.
6. Goto A., Yamada K., Ishii M. et al Purification and characterization of human urine-derived digitalis-like factor. *Biochem. Biophys. Res. Commun.* – 1998. - 154: 847–853.
7. Bagrov A.Y., Shapiro J.I. Endogenous digitalis: pathophysiologic roles and therapeutic applications. *Nat Clin Pract Nephrol.* – 2008. - 4: 378–392.
8. Kolmakova E.V., Haller S.T., Kennedy D.J. et al. Endogenous cardiotonic steroids in chronic renal failure *Nephrol Dial Transplant.* – 2011. -10: 1–8.
9. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis.* – 2002. - 39: 1–266.
10. Paczula A., Wi cek A., Piecha G. The role of endogenous cardiotonic steroids in pathogenesis of cardiovascular and renal complications of arterial hypertension. *Postepy Hig Med Dosw (Online).* – 2016. - 70: 243–250.
11. Sandtner W., Egwolf B., Khalili-Araghi F. Et al. Ouabain Binding Site in a Functioning Na<sup>+</sup>/K<sup>+</sup> ATPase. *J Biol Chem.* – 2011. – 286 (44): 38177–38183.
12. Cavalcante-Silva L.H.A. , Almeida Lima E. , Carvalho D.C.M. et al. Much More than a Cardiotonic Steroid: Modulation of Inflammation by Ouabain *Front Physiol.* – 2017. - 8: 895.

**Information about the author:**

**Burlaka Ie.A.** – MD, PhD. O.O. Bogomolets National Medical University, Department of Pediatrics №4, Kiev, Ukraine, Tolstogo street 10, 01004. E-mail address – evgbur1982@gmail.com

© Burlaka Ie.A., 2018